| MATERIALS AND METHODS

| Strains
A total of 2639 MTB isolates were collected by the Tianjin drugresistance tuberculosis surveillance program from Jan 2013 to Dec 2015. Identification of isolates was performed on Lowenstein-Jensen medium containing p-Nitrobenzoic-acid (PNB) and Thiophene-2-carboxylic hydrazide (TCH).
| Drug susceptibility test
According to the proportion method recommended by WHO, drug susceptibility tests (DSTs) were performed on Lowenstein-Jensen medium containing streptomycin (4 mg/L), rifampicin (40 mg/L), iso- 
| Patient information
The demographic and clinical information of enrolled patients, including gender, age, and TB treatment history, was obtained from the patients' records.
| DNA sequencing of gyrA and gyrB genes
DNA was extracted using the cetyltrimethylammonium bromide method, and samples were stored at −20°C. Primers used to amplify and sequence the QRDR of gyrA and gyrB from MTB isolates were described previously 11 and include GYRA-F: ATCGACTATGCGATGAGCG, GYRA-R:
GGGCTTCGGTGTACCTCAT, GYRB-F: AGTCGTTGTGAACAAGGCTGT, and GYRB-R: CCACTTGAGTTTGTACAGCGG. PCR products were sequenced by Thermo Fisher Scientific Inc. (Beijing, China). Sequence data was analyzed using the MUBII-TB-DB database and BLAST on http:// blast.ncbi.nlm.nih.gov, using the MTB H37Rv genome as a reference (GenBank accession number: CP003248.2). 
| Statistical analysis
A χ2 test in IBM SPSS Statistics 19.0 (SPSS Inc., Chicago, IL, USA) was used to compare the proportions of drug resistance mutations in gyrA and gyrB between isolates from new and previously treated TB patients. P values of <.05 were considered statistically significant.
| RESULTS
| Patients' information
By proportion method, 50 of 2639 isolates were OFX mono-resistant MTB, excluding six repeated OFX mono-resistant MTB isolates. Each of the 50 OFX mono-resistant MTB isolates obtained in this study were collected separately from 50 unrelated pulmonary TB patients (Table 1) .
| Mutations in gyrA and gyrB genes among MTB strains
As shown in Table 1 , 62% (31/50) isolates carried single mutations in the QRDR of gyrA. The most frequent mutations in gyrA were at positions D94N (n=7), A (n=6), G (n=6), and Y (n=2), followed by A90V
(n=5) and S91P (n=5). Of all MTB isolates, 4% (2/50) isolates carried single mutations in the QRDR of gyrB, at positions T539A and E540D, based on the findings of Pantel et al. 13 All strains carried S95T mutations in gyrA and are not listed in Table 1 
| DISCUSSION
In this study, the most common mutations in gyrA were found in the QRDR at positions 94, 90, and 91, carried by 62% OFX mono-resistant MTB isolates, which was in agreement with the previously findings from literatures. 5, 14 To our knowledge, this is the first report to show that the mutations T539A and E540D in the QRDR in gyrB were found from OFX mono-resistant MTB isolates in China. These mutations in gyrA and gyrB partially accounted for the phenotypic OFX resistance.
Other mechanisms of FQ resistance, such as efflux pumps, should be evaluated to improve the prediction of FQ resistance phenotypes.
15
All OFX mono-resistant MTB isolates were obtained from both new (42 cases) and previously treated TB patients (eight cases). Our results implied that the transmission of isolates that were already resistant to FQs causes the prevalence of FQ resistance and that MTB in TB patients acquires FQ resistance correlated with the patient's previous exposure to FQs. 16 However, no difference was detected between the proportions of isolates with mutations in gyrA/gyrB from new and previously treated TB patients (P=.820). A limitation was that only a small number of MTB isolates that had mutations in gyrA/gyrB were collected, excluding other OFX resistant MTB isolates.
| CONCLUSION
In conclusion, mutations in QRDR in both gyrA and gyrB were important in predicting OFX resistance of MTB isolates in Tianjin, China.
Further research using additional OFX resistant MTB isolates to acquire and analyze the prevalence of OFX genotypic resistance of MTB isolates in this region is needed.
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